Zhang Yi, Mo Chengjun, Ai Penghui, He Xiaoqin, Xiao Qin, Yang Xiaodong
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gut Microbes. 2025 Dec;17(1):2454937. doi: 10.1080/19490976.2025.2454937. Epub 2025 Jan 28.
Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the gut microbiota. Pharmacomicrobiomics, an emerging field focusing on the interplay of drugs and gut microbiota, provides a potential foundation for making certain advances in personalized medicine. Understanding the communication between gut microbiota and antiparkinsonian drugs is critical for precise treatment of Parkinson's disease. Here, we provide a historical overview of the interplay between gut microbiota and antiparkinsonian drugs. Moreover, we discuss potential mechanistic insights into the complex associations between gut microbiota and drug metabolism. In addition, we also draw attention to microbiota-based biomarkers for predicting antiparkinsonian drug efficacy and examine current state-of-the-art knowledge of microbiota-based strategies to optimize drug therapy in Parkinson's disease.
长期以来，作为药代动力学决定因素的肠道微生物群一直被忽视。近年来，越来越多的证据表明，肠道微生物群会影响药物代谢和疗效。相反，药物也会对肠道微生物群的功能和组成产生重大影响。药物微生物组学是一个新兴领域，专注于药物与肠道微生物群之间的相互作用，为个性化医学取得某些进展提供了潜在基础。了解肠道微生物群与抗帕金森病药物之间的相互作用对于帕金森病的精准治疗至关重要。在此，我们提供了肠道微生物群与抗帕金森病药物之间相互作用的历史概述。此外，我们讨论了对肠道微生物群与药物代谢之间复杂关联的潜在机制见解。此外，我们还关注基于微生物群的生物标志物以预测抗帕金森病药物疗效，并审视基于微生物群的策略在优化帕金森病药物治疗方面的当前最新知识。
